NasdaqGS:BBIOBiotechs
A Look At BridgeBio Pharma (BBIO) Valuation After FDA Priority Review For BBP-418
BridgeBio Pharma (BBIO) is back in focus after the FDA accepted its New Drug Application for BBP-418 with Priority Review for limb-girdle muscular dystrophy type 2I/R9, setting a PDUFA action date of November 27, 2026.
See our latest analysis for BridgeBio Pharma.
The FDA action has arrived while the share price has moved around, with a 7 day share price return of 3.44%, a year to date share price return down 13.58%, and a 1 year total shareholder return of 73.23% alongside a very large 3...